Table 1.
Baseline demographics and clinical characteristics
| Icodec LD (n = 54) | Icodec NLD (n = 50) | IGlar U100 (n = 50) | Total (N = 154) | |
|---|---|---|---|---|
| Age, years | 62.4 ± 7.2 | 62.1 ± 8.2 | 60.5 ± 7.9 | 61.7 ± 7.8 |
| Male, n (%) | 39 (72.2) | 39 (78.0) | 33 (66.0) | 111 (72.1) |
| Duration of type 2 diabetes, years | 13.8 ± 7.7 | 16.8 ± 8.2 | 14.8 ± 8.1 | 15.1 ± 8.1 |
| Ethnicity, n (%) | ||||
| White | 46 (85.2) | 39 (78.0) | 44 (88.0) | 129 (83.8) |
| Asian | 4 (7.4) | 9 (18.0) | 3 (6.0) | 16 (10.4) |
| Black or African American | 3 (5.6) | 2 (4.0) | 3 (6.0) | 8 (5.2) |
| Native Hawaiian or other Pacific Islander | 1 (1.9) | 0 | 0 | 1 (0.6) |
| BMI, kg/m2 | 30.2 ± 4.3 | 29.0 ± 4.1 | 30.3 ± 5.0 | 29.8 ± 4.5 |
| FPG, mmol/L | 7.9 (1.9)* | 8.0 (2.3) | 8.2 (2.0)† | 8.0 (2.1) |
| FPG, mg/dL | 142 ± 34* | 144 ± 41 | 148 ± 36† | 144 ± 37 |
| HbA1c, % | 7.8 (0.7) | 7.9 (0.7) | 7.9 (0.7) | 7.9 (0.7) |
| HbA1c, mmol/mol | 62.0 (7.4) | 63.3 (8.0) | 63.2 (7.8) | 62.8 (7.7) |
| TIR at baseline, % | 58.9 (23.2) | 54.5 (20.2) | 58.7 (21.5) | 57.4 (21.7) |
| Total insulin dose‡ (CV%), units | 22.5 (61.0) | 24.5 (47.7) | 24.0 (49.2) | 23.6 (52.8) |
| Basal insulin at screening, n (%) | ||||
| Insulin degludec | 4 (7.4) | 15 (30.0) | 7 (14.0) | 26 (16.9) |
| Insulin detemir | 9 (16.7) | 3 (6.0) | 1 (2.0) | 13 (8.4) |
| Insulin glargine U100 | 32 (59.3) | 23 (46.0) | 37 (74.0) | 92 (59.7) |
| Insulin glargine U300 | 9 (16.7) | 8 (16.0) | 5 (10.0) | 22 (14.3) |
| NPH (isophane) insulin | 0 | 1 (2.0) | 0 | 1 (0.6) |
Data are mean (SD) unless otherwise indicated. All percentages are subject to rounding. CV%, coefficient of variation.
*
n = 52.
†
n = 49.
‡
Geometric mean.